Aurobindo Pharma Q1FY27 Revenue Up 16.3% to ₹9,150 Cr; Net Profit Rises 25.2%
Aurobindo Pharma reported Q1FY27 revenue of ₹9,150 Cr, up 16.3% YoY, and net profit of ₹1,032 Cr, up 25.2% YoY. The company launched 10 products in the US and generated US$98 million in free cash flow. CuraTeQ Biologics filed Denosumab with EMA and is preparing for U.S. FDA filings.
The announcement details significant financial growth, strategic advancements in the biosimilars and contract manufacturing segments, and successful product launches, all of which are material to investors and have a high impact on the company's outlook.
The company reported strong year-on-year growth in revenue and net profit, driven by robust performance across key business segments and successful product launches. Positive developments in the biosimilars segment and a healthy cash flow position further contribute to a positive sentiment.
Aurobindo Pharma Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a consolidated revenue of ₹9,150 crore, marking a 16.3% increase year-on-year. EBITDA stood at ₹1,924 crore, a 20.0% rise, and Net Profit surged by 25.2% to ₹1,032 crore.
The growth was driven by strong performance across all business areas, with the U.S. base business continuing to grow due to volume gains and new launches. The company launched 10 products and received final approval for 10 products in the U.S. market during the quarter. Net Capex was US$ 78 million, primarily for capability enhancements and new business developments.
The company generated free cash flow of US$ 98 million during the quarter, maintaining a net cash position of approximately US$ 42 million as of June 30, 2026, after significant payments for the Lannett acquisition (US$ 247 million) and a share buyback (US$ 85 million).
Geographically, the U.S. market contributed 41.2% of consolidated revenue. Europe saw a 25.6% year-on-year growth, and Growth Markets reported a 37.7% increase. API revenues rose by 14.6% year-on-year.
In its biosimilars and biologics contract manufacturing update, CuraTeQ Biologics secured ANVISA GMP certification and filed Denosumab with CHMP/EMA. Omalizumab filing is on track for Q3 2026, and initial U.S. FDA filings for Omalizumab, Denosumab, and Bevacizumab are imminent. Commercial expansion is underway in the UK, Europe, and LATAM, with new distribution agreements in place.
TheraNym, the biologics contract manufacturing arm, is progressing with Unit 1 inauguration and Unit 2 greenfield build. The merger of AuroVaccines into CuraTeQ is on track for completion by March 2027. The company also reported a robust pipeline with significant future market opportunities.
Aurobindo Pharma (Excl. Specialty & Injectables) has 737 approved ANDAs, with 33 awaiting final approval and 126 under review.
What to do with a filing like this
Aurobindo Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aurobindo Pharma Limited. Read the original for the full detail.